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Introduction
Hereditary leiomyomatosis and renal cell cancer syn-
drome (HLRCC) is an autosomal dominant condition, 
characterized by the development of  cutaneous leiomy-
omas, multiple uterine leiomyomas, and an aggressive 
form of  type 2 papillary renal cell carcinoma (RCC) (1–3). 
HLRCC is caused by germline mutation of  the fuma-
rate hydratase (FH) gene, and about 15% of  individuals 
with FH mutations develop HLRCC-associated RCC  (4). 
This type of  RCC is aggressive with a median overall sur-
vival of  15.8 months for stage III or stage IV disease  (3). 
Because of  its rarity, no standard treatment has been 
established for advanced or metastatic disease. We report 
a case of  advanced HLRCC-associated RCC, in which 
clinical features mimicked advanced renal pelvic cancer, 
and long-term survival was achieved with cytoreductive 
nephrectomy (CN), followed by a sequence of  axitinib and 
nivolumab. Although there is no prior clinical evidence, the 
molecular and biological characteristics of  the disease sup-
port therapeutic roles for these treatments in the manage-
ment of  metastatic HLRCC-associated RCC.
Case Report
A 65-year-old Japanese male diagnosed with left renal pel-
vic cancer was referred to us. He had visited another hospital 
due to gross hematuria. Incidentally, his daughter had under-
gone nephrectomy for kidney cancer at the age of 36 years. 
Physical examinations, including the skin, revealed no abnor-
mal findings. Laboratory findings showed hematuria, ele-
vated serum creatinine (1.47 mg/dL), and C-reactive protein 
(12.1 mg/L). Urine cytology showed atypical urothelial cells. 
Computed tomography (CT) scans identified a moderately 
enhanced mass occupying the left renal pelvis, in addition to 
hydronephrosis, multiple para-aortic lymphadenopathy, and 
left adrenal swelling (Figure 1).
Differential diagnosis included urothelial carcinoma of 
the renal pelvis, collecting duct carcinoma, and other rare 
types of RCC, which were less likely. Considering that locally 
advanced disease of either urothelial carcinoma of the renal 
pelvis or collecting duct carcinoma was probable, the patient 
was started on systemic chemotherapy with gemcitabine and 
cisplatin. However, his disease progressed slowly after six 
courses (7 months) of chemotherapy.
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Owing to the poor response of the tumor to chemotherapy 
with gemcitabine and cisplatin, we considered the probability 
of rare types of RCC and proposed nephrectomy for patho-
logical diagnosis along with mass reduction. The patient 
underwent CN with sampling of renal hilar lymphadenop-
athy with an uneventful postoperative course. Grossly, the 
tumor comprised multiple nodules spreading over the renal 
parenchyma and a solid pelvic mass (Figure 2A). Microscop-
ically, the tumor consisted of carcinoma cells with abundant 
eosinophilic cytoplasm and large nuclei arranged in a pap-
illary architecture, which was consistent with type 2 pap-
illary RCC (Figure 2B). We suspected HLRCC-associated 
RCC because of the patient’s family history. Immunohisto-
chemistry revealed no expression of FH in carcinoma cells 
 (Figure 2C). Germline genetic testing revealed heterozygous 
FH deletion in exon 2 (c.247_267del), confirming the diagno-
sis of HLRCC-associated RCC. Finally, a pathological diag-
nosis of HLRCC-associated RCC, pT3apN2 (stage IV), was 
made. The same FH mutation was also found in his daugh-
ter with a previous history of kidney cancer and his brother 
among five relatives examined (Figure 3).
24y 22y 16y38y
66y 61y
94y72y AMI
WT WT WT
Diagnosis 36y
mut
mut mut
Figure 3: Family pedigree. Ages shown are those at which 
subjects took genetic testing. An arrow indicates the present 
case. AMI, acute myocardial infarction; mut, germline muta-
tion of the fumarate hydratase gene; WT, wild type.
Figure 1: Computed tomography at the first visit. A moderately enhanced mass occupies the left renal pelvis, accompanying 
hydronephrosis and multiple para-aortic lymphadenopathy (arrows).
(A) (B) (C)
Figure 2: Pathological findings of nephrectomy specimen. Macroscopic findings (A), microscopic findings (B), hematoxylin and 
eosin stain, ×200), and immunohistochemistry of fumarate hydratase (C, ×200).
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To assess the metabolic activity of HLRCC-associated 
RCC, fluorodeoxyglucose–positron emission tomography 
(FDG-PET) was performed. It showed strong accumu-
lation in para-aortic lymph nodes, the left adrenal gland, 
and focally in the 12th thoracic to the third lumbar verte-
brae. Metabolic tumor volume (MTV) and total lesion gly-
colysis (TLG) were 215.3 cm³ and 1042.5 g, respectively 
 (Figure  4A). Axitinib was initiated following radiotherapy 
at 30 Gy in 10 fractions in combination with zoledronic 
acid to bone metastases, which achieved a partial response 
 (Figure  4C, 4D). Nivolumab was started 7 months after 
starting axitinib. The patient had been in sustained partial 
response on nivolumab, with significant reductions in MTV 
and TLG of 15.8 cm³ and 112.5 g, respectively, at 8 months 
after the start of nivolumab (Figure 4B, 4E). However, bilat-
eral adrenal metastases progressed 18 months after the start 
of the systemic sequential therapy. He re-started axitinib 
(progressive disease 10 months later), followed by everolimus 
(stable disease but discontinued due to hepatic and renal tox-
icities 2 months later) and re-challenge of nivolumab. He is 
alive with disease on nivolumab beyond slowly progressive 
disease 48 months after CN (58 months after the diagnosis 
of advanced kidney cancer). 
(A) (B)
(C) (E)(D)
Figure 4: FDG-PET before axitinib (A) and 8 months 
after nivolumab following 7-months of axitinib (B). Met-
abolic tumor volume (MTV) was defined as the tumor 
volume greater than 40% of standardized uptake value 
(SUV) max. Total lesion glycolysis (TLG) was calculated 
as MTV×SUVmean. MTV and TLG were calculated by 
using LIFEx package (www.lifexsoft.org). MTV/TLG are 
215.3 cm³/1042.5 g (A) and 15.8 cm³/112.5 g (B). CT before 
axitinib (C), 6 months after axitinib (D), and 7 months after 
nivolumab (E).
Discussion
It is challenging to differentiate infiltrative nonclear cell renal 
cell carcinoma (nccRCC) accompanied by hydronephrosis 
from invasive renal pelvic cancer and collecting duct carci-
noma. In the present case, systemic chemotherapy was initially 
given based on the clinical diagnosis of advanced urothelial 
carcinoma or collecting duct carcinoma, which eventually 
delayed treatment for advanced HLRCC- associated RCC. 
Biopsy should be considered with a possible diagnosis of 
hereditary RCC in mind in the case of a positive family his-
tory of juvenile kidney cancer, although other clinical features 
indicate renal pelvic cancer or collecting duct carcinoma.
Genetic testing and counseling should be offered to at-risk 
family members. Given the aggressive nature of HLRCC- 
related RCC, individuals harboring a pathogenic FH muta-
tion should be placed on surveillance, including annual 
renal magnetic resonance imaging (3). Our patient’s healthy 
brother with a germline FH mutation is also on surveillance.
Upfront, CN is currently not recommended for all of 
metastatic RCC patients treated with tyrosine kinase inhib-
itors (TKIs), based on the results of two randomized trials 
for metastatic clear cell RCC (ccRCC) (5, 6). As for meta-
static papillary RCC, in which TKIs were less effective than 
in ccRCC, a prognostic benefit of CN was reported in spite 
of a retrospective study using the International Metastatic 
RCC Database Consortium (IMDC) database (7). No data 
are available on the prognostic role of CN for metastatic 
HLRCC-associated RCC.
Biologically, HLRCC-associated RCC is characterized by 
the accumulation of fumarate, which induces subsequent 
stabilization of hypoxia-inducible factors (HIFs) (8) and 
nuclear factor E2-related factor 2 (NRF2) accumulation (9), 
leading to a Warburg-like metabolic shift to glycolysis- 
dependent metabolism (2, 10). In fact, HLRCC-associated 
RCC shows remarkably high glucose uptake on FDG-
PET (11), as observed in the present case. Of note, pretreatment 
MTV and TLG have been reported as prognostic biomark-
ers in metastatic RCC patients treated with TKIs; increased 
MTV and TLG are reportedly associated with worse prog-
nosis (12). In our case, CN was conducted mainly for diag-
nostic purpose. Given that TKIs are potentially effective for 
metastatic HLRCC-associated RCC, as discussed later, CN 
or other debulking surgery may have a prognostic role by 
reducing MTV and TLG prior to TKI therapy.
No standard of care has been established for metastatic 
HLRCC-associated RCC. With the concept of inhibiting 
HIF-dependent angiogenesis and glucose uptake by dual 
blockade of vascular endothelial growth factor receptor/
epidermal growth factor receptor, bevacizumab and erlotinib 
are being tested in a phase II clinical trial (NCT01130519). In 
the first 20 patients with HLRCC-associated RCC, an over-
all response rate of 65% was reported (13). A randomized 
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phase II study comparing a c-MET inhibitor cabozantinib 
with sunitinib for metastatic papillary RCC is also ongoing 
(NCT02761057). Axitinib was administered in two cases of 
HLRCC-associated RCC as an alternative systemic therapy 
and was found to be effective in one case (14, 15); a patient 
with regional lymph node metastasis receiving axitinib in a 
neoadjuvant setting showed major pathological response 
and remained disease-free for over 33 months after radical 
nephrectomy and regional lymph node dissection (14). In the 
present case, axitinib following CN was also effective; treat-
ment for a period of 7 months profoundly reduced the tumor 
volume.
Although immune checkpoint inhibitors (ICIs) are cur-
rently the standard of care for metastatic RCC, there is 
limited evidence on their efficacy for nccRCC. The overall 
response rate of ICIs for nccRCC was about 20% (16, 17). 
In three young cases of papillary RCC, nivolumab achieved 
a durable response (18–20). However, no data are available 
on the activity of ICIs for HLRCC-associated RCC. In 
general, higher tumor mutation burden (TMB) and a resul-
tant increase in tumor neoantigens are associated with bet-
ter outcomes with ICIs (21). In spite of the moderate TMB 
measured by whole exon sequencing, frequent frameshift 
insertions and deletions produce more neoantigens than 
expected according to the TMB in RCC, irrespective of the 
histological type (22). In HLRCC-associated RCC, accu-
mulating fumarate impairs homologous recombination 
DNA repair (23), increasing insertions and deletions, and 
consequently increasing the number of neoantigens (22). In 
addition, the majority of HLRCC-associated RCC cases are 
categorized as CpG island methylation phenotype (CIMP) 
based on molecular profiling (24), which is characterized by 
increased immune cell infiltrate gene expression signature 
similar to ccRCC, thereby eliciting a favorable response to 
ICIs (24). These molecular characteristics suggest the effi-
cacy of ICIs for HLRCC-associated RCC.
In our case, nivolumab sustained stable disease for 11 
months after the tumor volume had been significantly 
reduced by axitinib. Lower MTV on FDG-PET was reported 
to be associated with more favorable outcomes of  ICIs in 
advanced melanoma (25) and NSCLC (26). It remains to be 
elucidated whether that is the case or not in metastatic RCC.
In the present case, long-term survival (48 months from 
CN and 58 months from the diagnosis of advanced kidney 
cancer) was achieved through multidisciplinary sequen-
tial treatment consisting of CN, radiation, axitinib, and 
nivolumab. Given that all nine patients with stage III or stage 
IV HLRCC-associated RCC in a previous report died within 
3 years (3) and the median survival was about 1 year for 
CIMP-RCC patients (24), the multidisciplinary sequential 
treatment seems to have prolonged survival in our case. Fur-
ther investigations are needed to evaluate the efficacy of such 
a therapeutic strategy for this rare and aggressive disease.
Conclusion
We experienced a case of metastatic HLRCC-associated 
RCC, in which clinical features mimicked advanced renal 
pelvic cancer. Biopsy should be considered with a possible 
diagnosis of hereditary RCC in mind, particularly in the 
case of a positive family history of juvenile kidney cancer. In 
this case, long-term survival was achieved with multimodal 
sequential treatment consisting of CN, radiation to bone 
metastases, axitinib, and nivolumab. In spite of no prior clin-
ical evidence, the molecular and biological characteristics of 
the disease support therapeutic roles for these treatments in 
the management of metastatic HLRCC-associated RCC.
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